EOFlow Co Ltd

EOFlow's capital structure is highly leveraged, with total liabilities of KRW 182.6 billion and total equity of -KRW 146.2 billion, resulting in a negative debt-to-equity ratio of -0.13. The company's liquidity position is weak, with cash and equivalents of KRW 3.45 billion and a current ratio of 0.04, indicating significant short-term financial stress. Profitability metrics are deeply negative, with a net loss of KRW 42.3 billion and an operating loss of KRW 22.8 billion. Return on equity is 28.93%, but this is misleading due to the negative equity base. Return on assets is -1.163%, reflecting poor asset utilization and operational performance. The company's revenue is concentrated in a single business line focused on wearable medical devices and insulin management systems. No geographic diversification is disclosed, and the company operates primarily in South Korea, exposing it to regional market risks. Growth prospects are constrained by the company's current financial position. Revenue of KRW 3.67 billion is significantly below industry benchmarks, and the outlook for the current and next fiscal years is not provided in the data. The company's negative operating and free cash flows suggest limited capacity for organic growth or investment. Risk factors include high leverage, negative equity, and weak liquidity. The risk assessment flags a negative net cash position after subtracting total debt. Dilution risk is currently low, but the company's negative equity and high debt levels could necessitate future equity issuance, which would dilute existing shareholders. Recent filings and transcripts are not provided in the input data, so no specific recent events can be cited. However, the company's financial snapshot indicates ongoing operational and liquidity challenges that may be discussed in recent disclosures.